Clinical Gastroenterology and Hepatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort
Ultrasound-guided attenuation parameter (UGAP) is recently developed for noninvasive evaluation of steatosis. However, reports on its usefulness in clinical practice are limited. This prospective multicenter study analyzed the diagnostic accuracy of grading steatosis with reference to magnetic resonance imaging-based proton density fat fraction (MRI-PDFF), a non-invasive method with high accuracy, in a large cohort. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 9, 2021 Category: Gastroenterology Authors: Kento Imajo, Hidenori Toyoda, Satoshi Yasuda, Yasuaki Suzuki, Katsutoshi Sugimoto, Hidekatsu Kuroda, Tomoyuki Akita, Junko Tanaka, Yutaka Yasui, Nobuharu Tamaki, Masayuki Kurosaki, Namiki Izumi, Atsushi Nakajima, Takashi Kumada Source Type: research

Esophageal dysmotility is associated with disease severity in eosinophilic esophagitis
An association of eosinophilic esophagitis (EoE) with esophageal dysmotility has been described, however the related mechanism remains unclear. We aimed to evaluate clinical and physiologic characteristics, including esophageal distensibility, associated with secondary peristalsis in patients with EoE. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 9, 2021 Category: Gastroenterology Authors: D.A. Carlson, C. Shehata, N. Gonsalves, I. Hirano, S. Peterson, J. Prescott, D.A. Farina, J.M. Schauer, W. Kou, P.J. Kahrilas, J.E. Pandolfino Source Type: research

Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry
Globally, nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. We assessed clinical presentation and patient-reported outcomes (PROs) among NAFLD patients from different countries. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 9, 2021 Category: Gastroenterology Authors: Zobair M. Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vincent Wai-Sun Wong, Marlen Castellanos Fernandez, Vasily A. Isakov, Ajay K. Duseja, Nahum Mendez-Sanchez, Yuichiro Eguchi, Elisabetta Bugianesi, Patrizia Burra, Jacob George, Jian-Gao Fan, George V. Papath Source Type: research

Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study
Nonalcoholic fatty liver disease (NAFLD) is associated with sugar-sweetened beverage (SSB) consumption in cross-sectional studies. In a prospective cohort, we examined the association of beverage consumption (SSB and diet soda) with incident NAFLD and changes in hepatic fat in the Framingham Heart Study (FHS). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: William Y. Park, Ioanna Yiannakou, Julie M. Petersen, Udo Hoffmann, Jiantao Ma, Michelle T. Long Source Type: research

Decompensation in Patients With Advanced NAFLD: More Questions That Need Answering
Dear Editor: (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: Suprabhat Giri, Sridhar Sundaram Tags: Letter to the Editor Source Type: research

Therapeutics, Placebo, and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by a combination of recurrent abdominal pain and altered bowel habits.1 It is an international source of disease burden and affects an estimated 5% –10% of the adult population.1 It is also an important source of decreased quality of life, healthcare costs, and missed days of work and school.2,3 (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: Jeremy R. Glissen Brown, Anthony J. Lembo Tags: Editorial Source Type: research

Therapeutics, Placebo and the Importance of Hard Outcomes in Irritable Bowel Syndrome Research
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: Jeremy R. Glissen Brown, Anthony J. Lembo Tags: Editorial Source Type: research

Sugar-Sweetened Beverage, Diet Soda, and Non-Alcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study
Non-alcoholic fatty liver disease (NAFLD) is associated with sugar-sweetened beverage (SSB) consumption in cross-sectional studies. In a prospective cohort, we examined the association of beverage consumption (SSB and diet soda) with incident NAFLD and changes in hepatic fat in the Framingham Heart Study (FHS). (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: William Y. Park, Ioanna Yiannakou, Julie M. Petersen, Udo Hoffmann, Jiantao Ma, Michelle T. Long Source Type: research

Monitoring Colonoscopy Quality
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: Ravi Thiruvengadam Source Type: research

Decompensation in patients with advanced NAFLD – more questions that need answering
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 6, 2021 Category: Gastroenterology Authors: Suprabhat Giri, Sridhar Sundaram Source Type: research

Cost-effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy among Patients with New-Onset Diabetes
Screening for pancreatic ductal adenocarcinoma (PDAC) in asymptomatic adults is not recommended, but patients with new-onset diabetes (NoD) have an eight times higher risk of PDAC than expected. A novel risk-tailored early detection strategy targeting high-risk NoD patients might improve PDAC prognosis. We sought to evaluate the cost-effectiveness of this strategy. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - November 1, 2021 Category: Gastroenterology Authors: Louise Wang, Frank I. Scott, Ben Boursi, Kim A. Reiss, Sankey Williams, Henry Glick, Yu-Xiao Yang Source Type: research

Underestimation of Cirrhosis-Related Mortality in the Medicare Eligible Population, 1999 –2018
In this study, we aimed to examine trends in liver-related mortality using this updated definition among the elderly and to identify changes by relevant subsets of gender, race, and rurality. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - October 30, 2021 Category: Gastroenterology Authors: Connor Griffin, Uchenna Agbim, Azaan Ramani, Nagasri Shankar, Fasiha Kanwal, Sumeet K. Asrani Tags: Research Letters Source Type: research

Underestimation of cirrhosis related mortality in the Medicare eligible population, 1999-2018
(Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - October 30, 2021 Category: Gastroenterology Authors: Connor Griffin, Uchenna Agbim, Azaan Ramani, Nagasri Shankar, Fasiha Kanwal, Sumeet K. Asrani Source Type: research

Limitations of Heartburn and Other Societies ’ Criteria in Barrett’s Screening for Detecting De Novo Esophageal Adenocarcinoma
Despite extensive Barrett ’s esophagus (BE) screening efforts, most patients with esophageal adenocarcinoma (EAC) present de novo. It is unclear how much of this problem is the result of insensitivity or poor applications of current screening guidelines. We aimed to evaluate the sensitivity of guidelines by determining the proportion of prevalent EAC cases that meet the American College of Gastroenterology (ACG) or the British Society of Gastroenterology (BSG) guidelines for BE screening and determine whether changes to criteria would enhance detection. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - October 29, 2021 Category: Gastroenterology Authors: Tarek Sawas, Shawn A. Zamani, Sarah Killcoyne, Andrew Dullea, Kenneth K. Wang, Prasad G. Iyer, Rebecca C. Fitzgerald, David A. Katzka Source Type: research

Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease —A Systematic Review
Globally, 25% of people have nonalcoholic fatty liver disease (NAFLD), and, currently, there are no approved pharmacologic treatments for NAFLD. With a slow disease progression, long-term impact of pharmacologic treatments can be assessed only by complementing emerging clinical trial evidence with data from other sources in disease progression modeling. Although this modeling is crucial for economic evaluation studies assessing the clinical and economic consequences of new treatments, the approach to modeling the natural history of NAFLD differs in contemporary research. (Source: Clinical Gastroenterology and Hepatology)
Source: Clinical Gastroenterology and Hepatology - October 29, 2021 Category: Gastroenterology Authors: Lina Gruneau, Mattias Ekstedt, Stergios Kechagias, Martin Henriksson Source Type: research